Robert Chang, MD
Glaucoma Specialist · Stanford, CANPI 1417044280
Payments from drug & device makers
Across 304 payments — averaging $1612.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$313K
- Alcon Research LLC$85K
- Alcon$41K
- Sight Sciences, Inc.$14K
- Carl Zeiss Meditec, Inc.$8K
- AbbVie$7K
- plus $22K from 19 others
Across 3 payments — averaging $4272.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$13K
What the payments were for
- Consulting fees$75,76772%
- Speaking & faculty fees$8,8988%
- Travel & lodging$5,7035%
- Food & beverage$15,13114%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 8 | $312,552 |
| Alcon Research LLC | 15 | $84,811 |
| Alcon | 152 | $40,841 |
| Sight Sciences, Inc. | 37 | $14,170 |
| Carl Zeiss Meditec, Inc. | 3 | $8,370 |
| AbbVie(2 entities) | 13 | $7,227 |
| Aerie Pharmaceuticals, Inc. | 12 | $5,413 |
| Ivantis, Inc | 7 | $2,949 |
| Glaukos Corporation | 13 | $2,876 |
| Iridex Corporation | 4 | $1,817 |
| Roche Products Limited | 1 | $1,714 |
| Carl Zeiss Meditec USA, Inc. | 8 | $1,572 |
| Omeros Corporation | 2 | $1,564 |
| Boston Scientific | 1 | $1,547 |
| Ocular Therapeutix, Inc. | 7 | $1,048 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $359 |
| NEW World Medical,inc. | 2 | $338 |
| Bausch & Lomb Americas Inc. | 3 | $205 |
| Tarsus Pharmaceuticals, Inc. | 2 | $204 |
| Eyepoint US, Inc. | 2 | $182 |
| Oyster Point Pharma, Inc. | 2 | $151 |
| Harrow Eye, LLC | 1 | $125 |
| Biogen | 2 | $109 |
| Nova Eye, Inc. | 1 | $90 |
| Beaver-visitec International, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$27,902
- NGENUITY$15,876
- OMNI(R) SURGICAL SYSTEM (US)$12,713
- Voyager DSLT$10,500
- XEN$6,102
- Rocklatan$4,826
- Rhopressa$4,479
- CIRRUS HD-OCT$3,755
- IOLMaster 700$3,632
- VERACITY SURGICAL$3,094
- VisuMax$3,094
- Humphrey HFA$2,600
- OMIDRIA$1,564
- GENERAL FEMALE SUI$1,547
- ARTEVO 800$1,268
- SION SURGICAL INSTRUMENT$1,125
- DURYSTA$725
- CLARUS$538
- FORUM$538
- Humphrey Field Analyzer (HFA3)$538
How this compares
$490,259 in reported general payments places this provider in the 95th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 65 | $46,574 |
| RocklatanNetarsudil Mesylat/Latanoprost | 76 | $43,527 |
| XiidraLifitegrast | 43 | $31,416 |
| Cyclosporine | 79 | $20,563 |
| TyrvayaVarenicline Tartrate | 21 | $18,984 |
| LumiganBimatoprost | 39 | $18,641 |
| RhopressaNetarsudil Mesylate | 40 | $15,826 |
| AzoptBrinzolamide | 17 | $12,882 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $9,757 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 43 | $9,317 |
| Methazolamide | 49 | $8,310 |
| Prednisolone Acetate | 202 | $7,947 |
| Brimonidine Tartrate | 80 | $7,066 |
| Alphagan PBrimonidine Tartrate | 12 | $6,465 |
| TafluprostTafluprost/Pf | 51 | $6,300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $7,227 | $81,437136 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $5,413 | $59,354116 claims |
| Bausch & Lomb Americas Inc.Xiidra | $205 | $31,41643 claims |
| AlconAzopt, Simbrinza | $40,841 | $22,19960 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $151 | $18,98421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Stanford
- Jeffrey GoldbergStanford$105K
- Sophia WangStanford$77K
- Yang SunStanford$2K
- Vikram ShankarStanford$1K
- Gala BeykinStanford$379
- Jason BacharachPetaluma$2.4M
- Jacob BrubakerSacramento$849K
- Andrew CampSan Diego$511K
- Billy PanBeverly Hills$251K
- Daniel KrivoyCulver City$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.